 |
brentuximab vedotin |
|---|---|
| Trade Name | Adcetris |
| Orphan Indication | Patients with peripheral T-cell lymphoma, not otherwise specified |
| USA Market Approval | USA |
| USA Designation Date | 2013-04-15 00:00:00 |
| Sponsor | Seattle Genetics, Inc.;21823 30th Drive Southeast;Bothell, Washington, 98021 |
